Keyphrases
Melanoma Patients
100%
Epitope
100%
Phase I Trial
100%
Immune Response
50%
Median Survival Time
50%
Stage IV Melanoma
50%
Immunohistochemistry
25%
Clinical Trials
25%
Dose-limiting Toxicity
25%
Intramuscular Injection
25%
Tumor
25%
IgG1 Antibody
25%
Electroporation
25%
DNA Vaccine
25%
Human IgG1
25%
T Cell Epitope
25%
TRP-2
25%
Clinical Response
25%
Gp100
25%
Dendritic Cells
25%
T Cells
25%
Adverse Events
25%
Vaccination
25%
Vaccine Target
25%
Tumor Cells
25%
ELISPOT
25%
T Cell Expansion
25%
Clinical Trial Information
25%
CDR Regions
25%
Injection Pain
25%
Human Lymphocytes
25%
Overall Survival Time
25%
Multiple Tumors
25%
Cellular Immune Response
25%
Escalating Dose
25%
Clinical Model
25%
Expansion Cohort
25%
Repeated Dose
25%
Tumor-like Lesions
25%
Metastatic Disease
25%
Expansion in Vitro
25%
Medicine and Dentistry
Epitope
100%
Nodular Melanoma
100%
Phase I Trials
100%
T Cell
60%
Clinical Trial
40%
Immune Response
40%
Median Survival Time
40%
Disease
20%
Immunohistochemistry
20%
Neoplasm
20%
Overall Survival
20%
DNA Vaccine
20%
In Vitro
20%
Lymphocyte
20%
Tumor Cell
20%
Immunoglobulin G1 Antibody
20%
Dendritic Cell
20%
Glycoprotein Gp 100
20%
Cell Expansion
20%
Electroporation
20%
Metastatic Carcinoma
20%
Survival Time
20%
Intramuscular Injection
20%
Proteus Syndrome
20%
Injection Site Pain
20%
Cellular Immunity
20%
Adverse Event
20%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Epitope
100%
Phase I Trials
100%
Neoplasm
40%
Clinical Trial
40%
Median Survival Time
40%
Disease
20%
Immunoglobulin G1 Antibody
20%
Intramuscular Injection
20%
Glycoprotein Gp 100
20%
DNA Vaccine
20%
Adverse Event
20%
Overall Survival
20%
Metastasis
20%
Vaccination Policy
20%
Elimination
20%
Multiple Cancer
20%
Injection Site Pain
20%
Survival Time
20%
Immunology and Microbiology
Epitope
100%
T Cell
60%
Vaccine Efficacy
60%
Immune Response
40%
Median Survival Time
40%
DNA Vaccine
20%
Immunoglobulin G1 Antibody
20%
Electroporation
20%
Dendritic Cell
20%
Vaccination Policy
20%
Tumor Cell
20%
Overall Survival
20%
Lymphocyte
20%
Adoptive Immunity
20%
Cell Expansion
20%
Survival Time
20%